Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Clinical trial NCT05174832 · UNKNOWN

Trial details

NCT number: NCT05174832
Sponsor: Fudan University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2022-09-07
Primary completion: 2023-12-01
Enrollment: 136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.